T-7

The dosage of Aesculus Hippocastanum Whole must be carefully calibrated based on the concentration of the active component, escin. Clinical studies, such as those reviewed by the Cochrane Collaboration, typically utilize standardized extracts.

• Chronic Venous Insufficiency: The standard adult dosage is 300 mg of a standardized extract (equivalent to 50 mg of escin) taken twice daily, approximately 12 hours apart. Some clinicians may start with a lower dose to assess tolerability.
• Topical Application: For gels or creams containing 1-2% escin, the product is typically applied to the affected area 2 to 3 times daily. It should be applied with a gentle upward motion toward the heart.

Aesculus Hippocastanum Whole is generally NOT recommended for use in children or adolescents under the age of 18. There is insufficient clinical data to establish the safety or efficacy of horse chestnut in the pediatric population. Parents should consult a pediatrician before administering any botanical supplement to a child.

Renal Impairment

Patients with pre-existing kidney disease should exercise extreme caution. While escin is primarily excreted via the bile, there have been rare reports of nephrotoxicity (kidney damage) associated with high-dose intravenous use or contaminated 'whole' preparations. Dosing may need to be reduced or avoided entirely in patients with a GFR (Glomerular Filtration Rate) below 30 mL/min.

Hepatic Impairment

Because the liver is the primary site of metabolism for Aesculus Hippocastanum, patients with hepatic insufficiency (liver failure or cirrhosis) should be monitored closely. No specific dose adjustment guidelines have been standardized, but a conservative approach is advised.

Elderly Patients

No specific dosage adjustments are typically required for geriatric patients; however, this population is at a higher risk for polypharmacy (taking multiple medications) and may be more sensitive to gastrointestinal side effects. Healthcare providers should assess the overall cardiovascular and renal health of elderly patients before initiating therapy.

• Administration: Oral forms should be swallowed whole with a full glass of water. Do not crush or chew sustained-release tablets, as this can lead to rapid absorption and increased risk of gastric irritation.
• Timing: It is best taken with or immediately after meals to minimize gastrointestinal upset.
• Consistency: Therapeutic effects for CVI may not be apparent for 4 to 6 weeks. It is crucial to take the medication consistently as prescribed by your healthcare provider.
• Storage: Store at room temperature (15°C to 30°C / 59°F to 86°F) in a dry place away from direct sunlight and moisture.

If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to 'catch up,' as this increases the risk of side effects.

Signs of overdose or poisoning (particularly if raw horse chestnut is accidentally ingested) include:

• Severe vomiting and diarrhea
• Muscle twitching or tremors
• Loss of coordination (ataxia)
• Dilated pupils
• Respiratory distress

In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Emergency measures may include gastric lavage and supportive care for respiratory or cardiovascular symptoms.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking the medication without medical guidance, as your symptoms may return or worsen.

Aesculus Hippocastanum Whole is generally well-tolerated when taken at recommended dosages, but some patients may experience mild adverse reactions. The most common side effects involve the digestive system:

• Gastrointestinal Upset: This includes nausea, stomach pain, or a feeling of fullness. This typically occurs shortly after taking the dose and can often be mitigated by taking the supplement with food.
• Dizziness: Some patients report a mild 'lightheaded' sensation, particularly when starting the treatment.
• Headache: A dull, transient headache may occur during the first few days of therapy.

• Pruritus (Itching): Some individuals may experience itchy skin, even without a visible rash.
• Flushing: A temporary reddening of the face or neck due to changes in vascular tone.
• Diarrhea: Loose stools may occur as the body adjusts to the saponin content.

• Nephrotoxicity: Rare instances of kidney inflammation or damage have been reported, primarily with high-dose parenteral (injected) use or impure preparations.
• Hepatotoxicity: Isolated cases of elevated liver enzymes have been noted in literature, though a direct causal link to standardized oral extracts is rare.
• Hypoglycemia: In some patients, Aesculus Hippocastanum may lower blood sugar levels, which can be problematic for those with diabetes.

> Warning: Stop taking Aesculus Hippocastanum Whole and call your doctor immediately if you experience any of the following serious symptoms:

• Anaphylaxis or Severe Allergic Reaction: Symptoms include swelling of the face, lips, or tongue; difficulty breathing; severe skin rash or hives; and a rapid drop in blood pressure.
• Unusual Bleeding or Bruising: Because horse chestnut may have mild antiplatelet effects, report any nosebleeds, bleeding gums, or large bruises that appear without injury.
• Signs of Kidney Failure: This includes a significant decrease in urine output, swelling in the ankles or feet, and persistent fatigue.
• Signs of Liver Dysfunction: Symptoms include yellowing of the skin or eyes (jaundice), dark urine, and severe upper abdominal pain.

Data on the continuous use of Aesculus Hippocastanum for longer than 6 months is limited. While many patients use it long-term for chronic venous insufficiency, it is recommended to have periodic evaluations by a healthcare provider. Long-term use without supervision could potentially mask the progression of deep vein thrombosis (DVT) or other serious vascular conditions. There is no evidence of addictive potential or cumulative toxicity with standardized oral extracts when used as directed.

There are currently no FDA black box warnings for Aesculus Hippocastanum Whole. However, the FDA does not evaluate botanical supplements with the same rigor as prescription pharmaceuticals. Patients should be aware that 'natural' does not always mean 'safe,' especially if the product is not standardized to remove the toxin esculin.

Report any unusual symptoms or persistent side effects to your healthcare provider. Monitoring your body's response is an essential part of safe therapy.

Aesculus Hippocastanum Whole should only be used under the supervision of a healthcare professional, particularly for patients with underlying chronic health conditions. The most critical safety concern is ensuring the product is free from esculin, a toxic component found in raw horse chestnut that can cause DNA damage and systemic poisoning. Always choose products from reputable manufacturers that specify 'esculin-free' or 'standardized extract' on the label.

No FDA black box warnings have been issued for Aesculus Hippocastanum Whole as of 2026.

• Allergic Reactions: Individuals with a known allergy to members of the Sapindaceae family or those with a history of latex allergy may be at a higher risk for cross-reactivity. Anaphylaxis, though rare, is a medical emergency.
• Bleeding Disorders: Aesculus Hippocastanum may interfere with platelet aggregation. Patients with hemophilia, von Willebrand disease, or those scheduled for surgery should avoid this supplement to prevent excessive bleeding.
• Diabetes Management: There is clinical evidence suggesting that horse chestnut can lower blood glucose levels. Patients with diabetes must monitor their blood sugar more frequently, as a dose adjustment of insulin or oral hypoglycemic agents may be necessary to prevent hypoglycemia (low blood sugar).
• Gastrointestinal Disease: Patients with active stomach ulcers, Crohn's disease, or ulcerative colitis should use this agent with caution, as the saponins can irritate the mucosal lining of the gut.

If you are taking Aesculus Hippocastanum Whole for an extended period, your healthcare provider may recommend the following monitoring:

• Liver Function Tests (LFTs): To ensure the liver is processing the supplement safely.
• Renal Function (BUN/Creatinine): To monitor kidney health, especially in patients with pre-existing renal concerns.
• Blood Glucose: For diabetic patients.
• Clinical Assessment of Edema: Regular measurement of leg circumference to evaluate treatment efficacy.

Aesculus Hippocastanum Whole generally does not cause sedation or cognitive impairment. However, if you experience dizziness or headaches when starting the medication, you should avoid driving or operating heavy machinery until you know how the supplement affects you.

While there is no direct contraindication, alcohol consumption can exacerbate venous insufficiency by causing vasodilation and may increase the risk of gastrointestinal irritation when combined with horse chestnut. It is advisable to limit alcohol intake while treating vascular conditions.

There is no known withdrawal syndrome associated with Aesculus Hippocastanum. However, if you stop taking the supplement abruptly, your symptoms of leg swelling and pain may return. It is best to discuss a tapering or maintenance plan with your doctor if you wish to discontinue use.

> Important: Discuss all your medical conditions, including any history of kidney or liver disease, with your healthcare provider before starting Aesculus Hippocastanum Whole.

While few drugs are strictly contraindicated, the following combinations carry significant risk:

• Potent Nephrotoxic Agents: Combining Aesculus Hippocastanum with drugs like Aminoglycosides (e.g., Gentamicin) should be avoided, as it may synergistically increase the risk of kidney damage.

• Anticoagulants and Antiplatelets: Drugs such as Warfarin (Coumadin), Clopidogrel (Plavix), Aspirin, and Enoxaparin (Lovenox) may have their effects amplified by horse chestnut. This increases the risk of internal bleeding and bruising. Healthcare providers should monitor the International Normalized Ratio (INR) or prothrombin time closely.
• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): Combining horse chestnut with Ibuprofen (Advil, Motrin) or Naproxen (Aleve) may increase the risk of gastric mucosal irritation and bleeding.

• Antidiabetic Medications: Since Aesculus Hippocastanum can lower blood sugar, it may enhance the effects of Metformin, Glipizide, or Insulin, potentially leading to hypoglycemia.
• Lithium: Horse chestnut may have a mild diuretic effect, which can decrease the excretion of lithium, leading to toxic levels of lithium in the blood. Patients on lithium therapy require frequent drug level monitoring.

• High-Fat Meals: May delay the absorption of escin, though it does not significantly reduce the total amount absorbed. Taking the supplement with a light meal is generally preferred to balance absorption and gastric comfort.
• Caffeine: No major interactions are known, but excessive caffeine can worsen symptoms of CVI by affecting vascular tone.

• Anticoagulant Herbs: Use caution when combining with Ginkgo Biloba, Garlic, Ginger, Ginseng, or Turmeric, as these also possess blood-thinning properties.
• Hypoglycemic Herbs: Supplements like Fenugreek, Bitter Melon, or Chromium may further lower blood sugar when taken with horse chestnut.

• Blood Glucose Tests: May show lower-than-expected results.
• Liver Enzymes: In rare cases, may show transient elevations.
• Coagulation Panels: PT/INR may be slightly prolonged in sensitive individuals.

For each major interaction, the mechanism usually involves either pharmacodynamic synergy (additive effects on blood thinning or blood sugar) or shared metabolic pathways. Management typically involves dose adjustment of the primary medication and frequent clinical monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous interactions.

Aesculus Hippocastanum Whole must NEVER be used in the following circumstances:

1. 1Severe Renal Failure: Due to the risk of nephrotoxicity, patients with end-stage renal disease or acute kidney injury must avoid this substance. The kidneys may not be able to process the metabolites, leading to systemic toxicity.
2. 2Known Hypersensitivity: Anyone who has experienced an allergic reaction to horse chestnut, escin, or any component of the formulation should not take it. Anaphylactic shock can occur upon re-exposure.
3. 3Raw Seed Ingestion: Ingesting raw, unprocessed horse chestnut seeds is absolutely contraindicated due to the presence of esculin, which can cause severe poisoning and death, especially in children.

Conditions requiring careful risk-benefit analysis by a physician include:

• Active Peptic Ulcer Disease: The saponins may aggravate the stomach lining.
• Bleeding Diathesis: A predisposition to bleeding makes the antiplatelet effects of horse chestnut potentially dangerous.
• Pregnancy and Lactation: Due to a lack of safety data, use is generally discouraged unless the benefits clearly outweigh the risks under strict medical supervision.
• Early Childhood: The risk of accidental poisoning and lack of pediatric data make this a relative contraindication for those under 18.

Patients with known allergies to the following may exhibit cross-sensitivity to Aesculus Hippocastanum:

• Latex: Some proteins in horse chestnut are structurally similar to those in Hevea brasiliensis (rubber tree).
• Other Sapindaceae: Related plants like Lychee or Rambutan may trigger similar allergic responses.

> Important: Your healthcare provider will evaluate your complete medical history, including any allergies or chronic diseases, before prescribing or recommending Aesculus Hippocastanum Whole.

Aesculus Hippocastanum Whole is generally classified as Category C (using the older FDA system) or considered to have insufficient data for a safety rating. There are no well-controlled studies in pregnant women. Some traditional practices use it for pregnancy-related varicose veins, but clinical guidelines typically recommend conservative treatments like compression stockings first. Potential risks include uterine stimulation or interference with fetal development. It should only be used if specifically directed by an obstetrician.

It is unknown whether the active components of Aesculus Hippocastanum pass into human breast milk. Because saponins can be irritating to the infant's developing gastrointestinal tract, breastfeeding mothers are generally advised to avoid this supplement. If use is deemed necessary, the infant should be monitored for diarrhea or skin rashes.

Horse chestnut is NOT approved for use in children. The primary concern in this population is the high risk of poisoning if the product is not properly processed or if raw seeds are found in nature and consumed. Furthermore, the vascular conditions horse chestnut treats are rare in children, making the risk-benefit profile unfavorable.

Elderly patients are the primary users of Aesculus Hippocastanum for CVI. While effective, this population is more likely to have reduced renal clearance and be on multiple medications (polypharmacy). There is an increased risk of falls if the supplement causes dizziness. Healthcare providers should prioritize monitoring kidney function and checking for drug-drug interactions with anticoagulants common in this age group.

For patients with mild to moderate renal impairment, the dose should be kept at the lower end of the therapeutic range (e.g., 50 mg escin once daily). In severe impairment (GFR < 30 mL/min), the drug should be avoided. Monitoring for signs of worsening kidney function is mandatory.

In patients with Child-Pugh Class A or B hepatic impairment, Aesculus Hippocastanum should be used with caution. Since the liver is responsible for the conjugation and metabolism of escin, liver failure could lead to increased systemic exposure and higher risk of side effects.

> Important: Special populations require individualized medical assessment. Never start a new supplement regimen in these groups without professional consultation.

Aesculus Hippocastanum Whole works primarily through its active saponin complex, escin. Escin increases the pressure in the veins by sensitizing the vascular smooth muscle to calcium ions, which enhances venous return. Simultaneously, it inhibits the enzymes hyaluronidase and elastase. These enzymes normally break down the 'glue' (extracellular matrix) that holds capillary walls together. By inhibiting them, escin reduces capillary pore size and decreases the 'leakiness' of the vessels. This leads to a reduction in the filtration of fluid into the tissues, effectively treating edema at its source.

The pharmacodynamic effect of Aesculus Hippocastanum is dose-dependent. Studies show that a minimum dose of 50 mg of escin is required to produce a measurable change in capillary filtration rates. The onset of action is slow; while some molecular effects occur within hours, the clinical reduction in leg swelling usually takes 2 to 4 weeks of consistent dosing. Tolerance does not typically develop, and the effects can persist for several days after discontinuation due to the high protein binding of escin.

| Parameter | Value |

|---|---|

| Bioavailability | 1% - 12.5% (Oral) |

| Protein Binding | >80% (primarily Albumin) |

| Half-life | 6 - 20 hours (Isomer dependent) |

| Tmax | 2 - 3 hours (Standardized extract) |

| Metabolism | Hepatic (Hydrolysis/Conjugation) |

| Excretion | Biliary/Fecal (>90%), Renal (<5%) |

The primary active constituent is Escin, a mixture of triterpene saponins. The molecular formula for the major component, beta-escin, is approximately C55H86O24 with a molecular weight of roughly 1131.26 g/mol. It is a white to cream-colored powder that is soluble in water and alcohol. The 'Whole' preparation also contains flavonoids (such as quercetin and kaempferol) and tannins, which contribute to its antioxidant profile.

Aesculus Hippocastanum is classified as a Phlebotonic or Venotonic agent. It belongs to the broader category of vascular protectives. It is often compared to synthetic vasoprotectives like Diosmin or Hesperidin and is considered a first-line botanical treatment for venous insufficiency in many international clinical guidelines.